Braun Stacey Associates Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Braun Stacey Associates Inc. grew its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 502,650 shares of the biopharmaceutical company's stock after purchasing an additional 59,845 shares during the quarter. Braun Stacey Associates Inc. owned approximately 0.32% of TG Therapeutics worth $19,819,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Arizona State Retirement System lifted its stake in TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after acquiring an additional 364 shares during the period. Golden State Wealth Management LLC grew its position in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 433 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after acquiring an additional 463 shares in the last quarter. NBC Securities Inc. increased its stake in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 823 shares in the last quarter. Finally, Redwood Investments LLC lifted its position in TG Therapeutics by 0.9% during the 4th quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company's stock valued at $2,846,000 after acquiring an additional 886 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Down 1.0%

TGTX traded down $0.37 during midday trading on Tuesday, reaching $35.61. The company's stock had a trading volume of 2,304,887 shares, compared to its average volume of 2,901,569. TG Therapeutics, Inc. has a 1 year low of $16.65 and a 1 year high of $46.48. The stock's 50-day moving average is $36.49 and its 200-day moving average is $35.19. The firm has a market capitalization of $5.65 billion, a price-to-earnings ratio of 148.38 and a beta of 1.91. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The business's quarterly revenue was up 90.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.07) EPS. As a group, research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director owned 228,816 shares of the company's stock, valued at $8,452,463.04. The trade was a 4.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.64% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.